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et al., 1994). JNK is activated by treatment of cells with
cytokines (e.g., TNF and IL-1) and by exposure of cells
to many forms of environmental stress (e.g., osmotic
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Department of Biochemistry and Molecular Biology stress, redox stress, and radiation) (reviewed by Ip and
Davis, 1998).University of Massachussetts Medical School
Worcester, Massachusetts 01605 The purpose of this review is to summarize recent
advances that have been made toward understanding
the JNK signaling pathway. It is now known that JNK
Cells respond to changes in the physical and chemical is required for embryonic morphogenesis and that this
signaling pathway contributes to the regulation of cellproperties of the environment. These changes include
alterations in the amount of nutrients, growth factors, proliferation and apoptosis. JNK also contributes to the
function of some differentiated cells. Thus, the JNK sig-cytokines, and adhesion to the cell matrix. In addition,
cells respond to physical stimulation mediated by osmo- nal transduction pathway is implicated in multiple physi-
ological processes.larity, heat, pH, redox, radiation, and mechanical stress.
These physical and chemical cues control many aspects
of cell function including migration, proliferation, differ- JNK Regulates AP-1 Transcription Activity
entiation, and death. The decision making process that Phosphorylation of c-Jun on the sites that are phosphor-
cells employ to mount an appropriate response to a ylated by JNK (Ser-63 and Ser-73) causes increased
specific stimulus is critical for normal life. Many signal transcription activity (Pulverer et al., 1991; Smeal et al.,
transduction pathways cooperate and participate in this 1991). Interestingly, JNK also phosphorylates other AP-1
process. Recent studies have established that mitogen- proteins, including JunB, JunD, and ATF2 (Ip and Davis,
activated protein kinases (MAPK) play an important reg- 1998). In each case, the sites of phosphorylation corre-
ulatory role. spond to Ser/Thr-Pro motifs located in the activation
Genetic studies have identified five MAPK pathways in domain of the transcription factor. Substrate recognition
the budding yeast Saccharomyces cerevisiae (Schaeffer by JNK requires a docking site to tether the kinase to
and Weber, 1999). These MAPK are essential for mating the substrate (Hibi et al., 1993). The mechanism that
(Fus3p), osmoregulation (Hog1p), sporulation (Smk1p), accounts for JNK-dependent regulation of AP-1 tran-
cell wall biosynthesis (Smk1p), and filamentation (Kss1p), scription activity is unclear, but a role for the coactivator
and these enzymes form a group with related structures CBP/p300 has been proposed (Arias et al., 1994). Addi-
and biochemical properties. Each MAPK is activated by tional JNK-dependent processes may also contribute
dual phosphorylation of a tripeptide motif (Thr-Xaa-Tyr) to the regulation of AP-1 activity. Thus, JNK may regu-
located in the activation loop (T-loop). This phosphoryla- late the intrinsic histone acetylase activity of ATF2 (Ka-
tion is mediated by a MAPK kinase (MAPKK) that is wasaki et al., 2000) and may regulate the ubiquitin-medi-
activated by phosphorylation by a MAPKK kinase ated degradation of AP-1 proteins (Fuchs et al., 1998c).
(MAPKKK). These MAPK are therefore activated by a A critical role for JNK appears to be the regulation of
kinase signaling cascade. AP-1 transcription activity. This conclusion is supported
MAPK signaling pathways have also been identified by genetic analysis of Jun and JNK in Drosophila and
in higher organisms. In mammals, three major groups by the analysis of AP-1 transcription activity in murine
of MAPK have been identified (Schaeffer and Weber, cells with targeted disruptions of genes that encode
1999). Each of these groups of MAPK is activated by a components of the JNK pathway (reviewed by Ip and
protein kinase cascade (Figure 1). The ERK and p38 Davis, 1998). JNK appears to be essential for AP-1 acti-
groups of MAPK are related to enzymes found in bud- vation caused by stress and some cytokines, but is not
ding yeast and contain the dual phosphorylation motifs required for AP-1 activation in response to other stimuli
Thr-Glu-Tyr and Thr-Gly-Tyr, respectively. The c-Jun (Yang et al., 1997a). The precise role of AP-1 in the
NH2-terminal kinases (JNK), also known as stress-acti- response to JNK activation is likely to be modified by
vated MAP kinases (SAPK), represent a third group of the activity of other transcription factors that interact
MAPK that has been identified in mammals. JNK con- with AP-1 on the promoters of target genes.
tains the dual phosphorylation motif Thr-Pro-Tyr.
Biochemical studies led to the identification and purifi- The JNK Group of MAPK
cation of JNK as a “p54 microtubule-associated protein The JNK protein kinases are encoded by three genes
kinase” that was activated by cycloheximide (Kyriakis (Table 1). The Jnk1 and Jnk2 genes are expressed ubiq-
and Avruch, 1990). JNK was found to bind the NH2- uitously. In contrast, the Jnk3 gene has a more limited
terminal activation domain of c-Jun (Adler et al., 1992; pattern of expression and is largely restricted to brain,
Hibi et al., 1993) and to phosphorylate c-Jun on Ser-63 heart, and testis. These genes are alternatively spliced to
and Ser-73 (Pulverer et al., 1991). Subsequently, JNK create ten JNK isoforms (Gupta et al., 1996). Transcripts
was molecularly cloned (Derijard et al., 1994; Kyriakis derived from all three genes encode proteins with and
without a COOH-terminal extension to create both 46
kDa nd 55 kDa isoforms. The functional significance*To whom correspondence should be addressed (e-mail: roger.davis@
umassmed.edu). of these splice variants is unclear. A second form of
Cell
240
part, by alterations in the function of the NFAT1 tran-
scription factor (Dong et al., 1998; Chow et al., 2000)
and by defects in IFNg secretion (Yang et al., 1998). In
contrast, one group has reported that JNK2 may be
required for T cell activation at low levels of stimulation
(Sabapathy et al., 1999a) and that the mechanism is
mediated, in part, by JNK-dependent regulation of IL-2
mRNA stability (Chen et al., 2000). Nevertheless, there is
agreement amongst all of these reports that at moderate
and high levels of immune challenge, JNK is not required
for T cell activation. However, JNK is required for ef-
fector T cell function (Dong et al., 2000). An important
question concerns why T cells are sensitive to defects
in JNK1 or JNK2 expression. This may result from the
pattern of JNK expression in murine T cells (Weiss et
al., 2000). Immature T cells (thymocytes) express high
levels of JNK1 and JNK2. However, JNK expression is
down-regulated in peripheral T cells. JNK is thereforeFigure 1. Stress-Activated MAPK Signaling Modules
expressed at low levels in naıˆve T cells, but the expres-The JNK and p38 MAPK are activated by dual phosphorylation on
Thr and Tyr caused by members of the MAPKK group of protein sion of JNK is up-regulated following immune challenge.
kinases. The MAPKK are activated, in turn, by phosphorylation medi- The low level of JNK expression in naıˆve T cells may
ated by a group of MAPKKK. Stress-activated MAPK signaling mod- account for the sensitivity of these cells to targeted
ules can be created through the sequential actions of a MAPKKK,
disruption of the Jnk genes.a MAPKK, and a MAPK.
Insight into the function of JNK protein kinases has
recently been achieved through the determination of the
atomic structure of JNK3 (Xie et al., 1998). Figure 2alternative splicing is restricted to the Jnk1 and Jnk2
illustrates the structure of the inactive complex of JNK3genes and involves the selection of one of two alterna-
with an ATP analog. The overall fold is typical of proteintive exons that encodes part of the kinase domain. This
kinases and is similar to other MAPK and consists ofalternative splicing influences the substrate specificity
two domains with an active site cleft. One significantof the JNK isoforms by altering the ability of JNK to
difference between JNK3 and other MAPK is that theinteract with docking sites on substrates (Gupta et al.,
ATP binding site is well-ordered in the inactive structure.1996). These docking sites are present in MAPKK, MAPK
The low activity appears to result from misalignment ofphosphatases, and MAPK substrates and appear to me-
active site residues and the location of the T-loop, whichdiate interactions with a common surface on JNK (Ta-
blocks access of substrates to the active site. MAPKKnoue et al., 2000). Initial studies indicated that the dock-
activate JNK by phosphorylation of the T-loop on Thring and substrate specificities of JNK1 and JNK2 were
and Tyr (Figure 2). Inactivation of JNK is mediated by adifferent. For example, c-Jun was preferentially bound
group of phosphatases, including Ser phosphatases,and phosphorylated by JNK1, while ATF2 was preferen-
Tyr phosphatases, and dual specificity phosphatasestially bound and phosphorylated by JNK2 (Kallunki et
(Keyse, 2000). The mechanism of JNK activation by dualal., 1994; Sluss et al., 1994). However, it is now clear that
phosphorylation is unclear, but it is likely that this phos-these differences reflect the particular spliced isoforms
phorylation may alter the structure of the T-loop andthat were examined. Different tissues express distinct
cause realignment of the NH2- and COOH-terminal do-repertoires of spliced JNK isoforms and the particular
mains to create a functional active site. A crystal struc-spliced isoform that preferentially targets a specific sub-
ture of activated JNK3 will be required to identify thestrate can be encoded by either the Jnk1 or the Jnk2
structural changes that occur during activation.genes (Gupta et al., 1996). The analysis of Jnk gene
disruptions in mice confirms that there is extensive com-
plementation between the Jnk genes and that there are JNK Is Activated by Two Dual-Specificity
Protein Kinasesalso tissue-specific defects in signal transduction that
may reflect the JNK isoform profile of individual tissues The JNK protein kinases are activated by phosphoryla-
tion on Thr and Tyr by MKK4 (also known as SEK1) and(Table 1). This complicates the analysis of Jnk knockout
mice and indicates the need for studies of compound MKK7. These protein kinases are expressed as a group
of alternatively spliced isoforms. Three MKK4 proteinmutants that lack expression of all JNK isoforms (Tour-
nier et al., 2000). kinases with distinct NH2-terminal regions have been
identified and six MKK7 protein kinase isoforms withMice deficient of JNK1 or JNK2 appear to be morpho-
logically normal. However, these mice are immunodefi- different NH2 termini and COOH termini have been de-
scribed. The mechanism that creates the different MKK4cient due to severe defects in T cell function (Constant
et al., 2000). No evidence for a defect in T cell activation isoforms has not been defined. In contrast, detailed
studies of the Mkk7 gene demonstrate that the isoforms(proliferation and IL-2 secretion) was obtained. Instead,
the deficiency was identified as a requirement of JNK result from both alternative splicing and the utilization
of different promoters (Tournier et al., 1999). These dif-for the appropriate differentiation of CD4 T helper cells
into effector cells (Dong et al., 1998, 2000; Yang et al., ferent forms of MKK4 and MKK7 are biochemically dis-
tinct (basal activity and inducibility) and are differentially1998). The mechanism was reported to be mediated, in
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Table 1. Components of the Mammalian JNK Signal Transduction Pathway
Alternative Name JNK Pathway Characterizationa Gene Disruptiona
MAPKKK
ASK1 MAPKKK5 1, 2
ASK2 MAPKKK6 3





MEKK4 MTK1 17, 18
MLK1 19
MLK2 MST 20




MKK4 SEK1, SERK1, SKK1, JNKK1 8, 26, 27 28–32
MKK7 SEK2, SKK4, JNKK2 33–38 39
MAPK
JNK1 SAPKg, SAPK1c 40–42 39, 43–47
JNK2 SAPKa, SAPK1a 41, 42, 48, 49 39, 44–46, 50–52
JNK3 SAPKb, SAPK1b, p49F12 41, 42, 53 54
Scaffolds
JIP1 IB1 55–57
JIP2 IB2 58, 59
JIP3 JSAP 60, 61
a References: 1Ichijo, H., et al. Science 275, 90–94 (1997); 2Wang, X.S., et al. J. Biol. Chem. 271, 31607–31611 (1996); 3Wang, X.S., et al. Biochem.
Biophys. Res. Commun. 253, 33–37 (1998); 4Hirai, S., et al. Oncogene 12, 641–650 (1996); 5Fan, G., et al. J. Biol. Chem. 271, 24788–24793
(1996); 6Sakuma, H., et al. J. Biol. Chem. 272, 28622–28629 (1997); 7Minden, A., et al. Science 266, 1719–1723 (1994); 8Yan, M., et al. Nature
372, 798–800 (1994); 9Lange-Carter, C.A., et al. Science 260, 315–319 (1993); 10Yujiri, T., et al. J. Biol. Chem. 274, 12605–12610 (1999); 11Minamino,
T., et al. Proc. Natl. Acad. Sci. USA 96, 15127–15132 (1999); 12Yujiri, T., et al. Proc. Natl. Acad. Sci. USA 97, 7272–7277 (2000); 13Yujiri, T., et
al. Science 282, 1911–1914 (1998); 14Xia, Y., et al. Proc. Natl. Acad. Sci. USA 97, 5243–5248 (2000); 15Blank, J.L., et al. J. Biol. Chem. 271,
5361–5368 (1996); 16Yang, J., et al. Nat. Genet. 24, 309–313 (2000); 17Gerwins, P., et al. J. Biol. Chem. 272, 8288–8295 (1997); 18Takekawa, M.,
et al. EMBO J. 16, 4973–4982 (1997); 19Dorow, D.S., et al. Eur. J. Biochem. 213, 701–710 (1993); 20Hirai, S., et al. J. Biol. Chem. 272, 15167–15173
(1997); 21Rana, A., et al. J. Biol. Chem. 271, 19025–19028 (1996); 22Teramoto, H., et al. J. Biol. Chem. 271, 27225–27228 (1996); 23Tibbles, L.A.,
et al. EMBO J. 15, 7026–7035 (1996); 24Yamaguchi, K., et al. Science 270, 2008–2011 (1995); 25Salmeron, A., et al. EMBO J. 15, 817–826 (1996);
26Derijard, B., et al. Science 267, 682–685 (1995); 27Lin, A., et al. Science 268, 286–290 (1995); 28Swat, W., et al. Immunity 8, 625–634 (1998);
29Yang, D., et al. Proc. Natl. Acad. Sci. USA 94, 3004–3009 (1997); 30Nishina, H., et al. J. Exp. Med. 186, 941–953 (1997); 31Nishina, H., et al.
Development 126, 505–516 (1999); 32Ganiatsas, S., et al. Proc. Natl. Acad. Sci. USA 95, 6881–6886 (1998); 33Tournier, C., et al. Proc. Natl. Acad.
Sci. USA 94, 7337–7342 (1997); 34Moriguchi, T., et al. EMBO J. 16, 7045–7053 (1997); 35Yao, Z., et al. J. Biol. Chem. 272, 32378–32383 (1997);
36Wu, Z., et al. Mol. Cell Biol. 17, 7407–7416 (1997); 37Lu, X., et al. J. Biol. Chem. 272, 24751–24754 (1997); 38Lawler, S., et al. FEBS Lett. 414,
153–158 (1997); 39Dong, C., et al. Nature 405, 91–94 (2000); 40Derijard, B., et al. Cell 76, 1025–1037 (1994); 41Sanchez, I., et al. Nature 372,
794–798 (1994); 42Gupta, S., et al. EMBO J. 15, 2760–2770 (1996); 43Dong, C., et al. Science 282, 2092–2095 (1998); 44Tournier, C., et al. Science
288, 870–874 (2000); 45Kuan, C.Y., et al. Neuron 22, 667–676 (1999); 46Sabapathy, K., et al. Mech. Dev. 89, 115–124 (1999); 47Constant, S.L., et
al. J. Immunol 165, 2671–2676 (2000); 48Kallunki, T., et al. Genes Dev 8, 2996–3007 (1994); 49Sluss, H.K., et al. Mol. Cell. Biol. 14, 8376–8384
(1994); 50Yang, D.D., et al. Immunity 9, 575–585 (1998); 51Sabapathy, K., et al. Curr. Biol. 9, 116–125 (1999); 52Chu, W.M., et al. Immunity 11,
721–731 (1999); 53Mohit, A.A., et al. Neuron 14, 67–78 (1995); 54Yang, D.D., et al. Nature 389, 865–870 (1997); 55Dickens, M., et al. Science 277,
693–696 (1997); 56Whitmarsh, A.J., et al. Science 281, 1671–1674 (1998); 57Bonny, C., et al. J. Biol. Chem. 273, 1843–1846 (1998); 58Negri, S.,
et al. Genomics 64, 324–330 (2000); 59Yasuda, J., et al. Mol. Cell. Biol. 19, 7245–7254 (1999); 60Ito, M., et al. Mol. Cell. Biol. 19, 7539–7548
(1999); 61Kelkar, N., et al. Mol. Cell. Biol. 20, 1030–1043 (2000).
activated by upstream MAPKKK (Tournier et al., 1999). entially phosphorylate JNK on Tyr and Thr, respectively
(Lawler et al., 1998). This difference in specificity sug-The MKK7 protein kinase is primarily activated by cyto-
kines (e.g., TNF and IL-1) and MKK4 is primarily acti- gests that MKK4 and MKK7 may cooperate to activate
JNK under some circumstances.vated by environmental stress. Comparison of the bio-
chemical properties of MKK4 and MKK7 demonstrates The MKK4 and MKK7 protein kinases are activated
by dual phosphorylation at two sites in the T-loop bythat while both protein kinases can activate JNK by dual
phosphorylation on Thr and Tyr, there are significant MAPKKK. Recent studies indicate an important role for
the protein phosphatase PP2Ca in the inactivation pro-differences in substrate specificity. First, MKK4, but not
MKK7, can also activate p38 MAPK. Whether MKK4 cess (Takekawa et al., 1998). The MAPKK may also be
inactivated during infection of cells with pathogens; foris a physiologically relevant activator of p38 MAPK is
unclear because p38 MAPK is also activated by MKK3 example, by the Yersinia pestis virulence factor, YpoJ,
and anthrax lethal factor (Duesbery et al., 1998; Orth etand MKK6 (Figure 1). Studies of compound mutant
Mkk32/2 Mkk62/2 cells will be required to resolve this al., 1999). Immunofluorescence analysis demonstrates
that both MKK4 and MKK7 are present in the cytoplasmquestion. Second, although MKK4 and MKK7 are dual
specificity protein kinases and do phosphorylate JNK and the nucleus (Tournier et al., 1999). Indeed, MKK7
may accumulate in the nucleus following exposure ofon both Thr and Tyr, MKK4 and MKK7 appear to prefer-
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and proliferation (Nishina et al., 1997). However, these
conclusions have not been supported by another study
which demonstrates that Mkk42/2 B and T cells develop
normally, that Mkk42/2 deficiency does not prevent JNK
activation in T cells, and that the mice develop lymph-
adenopathy with polyclonal expansion of both the B and
T cell compartments (Swat et al., 1998). Further studies
are required to resolve the differences between these
reports. However, the observation that Mkk4 gene dis-
ruption does not block JNK activation in T cells indicates
that Mkk7 may complement the Mkk4 deficiency. A criti-
cal role for MKK7 is supported by the results of the analysis
of Mkk72/2 T cells which are defective in JNK activation
(Dong et al., 2000). However, Mkk72/2 CD41 T cells do
not exhibit defects in activation, including IL-2 secretion.
Studies of compound mutant cells deficient of both the
Mkk4 and Mkk7 genes will be critical for future studies.
The JNK Pathway Is Activated by a Large Group
of MAPKKK
Several MAPKKK have been reported to activate the
JNK signaling pathway. These include members of the
MEKK group (MEKK1 though 4), the mixed-lineage pro-
tein kinase group (MLK1, MLK2, MLK3, DLK, and LZK),
the ASK group (ASK1 and ASK2), TAK1, and TPL2 (Table
1). In most cases, the evidence is based upon transfec-
tion assays (overexpression and dominant-negative ex-
periments) and in vitro protein kinase assays that dem-
onstrate phosphorylation and activation of MKK4 and/
or MKK7. However, these data do not establish whetherFigure 2. The Atomic Structure of JNK
these MAPKKK are physiological regulators of the JNKA ribbon diagram illustrates the three-dimensional structure of the
pathway. It is also unclear which MAPKKK are relevantinactive (nonphosphorylated) form of JNK3. The active site is occu-
pied by the ATP analog adenylyl imidodiphosphate (yellow) and two to specific physiological stimuli. This uncertainty is
Mg21 ions (orange). The T-loop is colored red and the two sites of caused by possible functional redundancy and by the
activating phosphorylation (Thr and Tyr) are indicated as red balls. promiscuity of function observed in overexpression and
Disordered regions are indicated with dashes. in vitro assays. Thus, many of these MAPKKK can acti-
vate more than one MAPK pathway and also the NF-kB
pathway in transfection assays. Whether this reflectscells to stress (Merritt et al., 1999). The nuclear localiza-
tion of MKK4 and MKK7 contrasts with the cytoplasmic the in vivo function or whether it is an artifact of overex-
pression is unclear. These same considerations applylocation (caused by nuclear export) of the ERK activators
MEK1 and MEK2. JNK may therefore be activated in the to the numerous Ste20-related protein kinases that acti-
vate the JNK pathway in transfection assays, althoughnucleus and the cytoplasm.
Targeted gene disruption experiments in mice demon- in this case the problem is further confounded because
the mechanism by which these Ste20-related proteinstrate that both MKK4 and MKK7 are required for embry-
onic development (Table 1). The cause of Mkk72/2 em- kinases activate the JNK cascade is unknown. The bio-
chemical properties of Ste20-related protein kinasesbryonic death is unclear (Dong et al., 2000). However,
the death of Mkk42/2 embryos appears to be caused by and MAPKKK have recently been reviewed in detail
(Fanger et al., 2000).liver apoptosis (Ganiatsas et al., 1998; Nishina et al.,
1999). This phenotype is similar to that observed for Gene disruption studies represent an important step
toward understanding the function of MAPKKK in thec-Jun2/2 embryos (Hilberg et al., 1993). However, it is
unlikely that defects in c-Jun phosphorylation contribute JNK pathway. Such studies have not been reported for
most of the candidate MAPKKK. However, significantto the Mkk42/2 phenotype because mutational removal
of the JNK phosphorylation sites in c-Jun causes no progress has been made toward understanding the
function of the MEKK group of MAPKKK using geneobvious embryonic abnormality (Behrens et al., 1999).
The mechanism that accounts for the defect in liver targeting methods in mice (Table 1). Mice deficient of
MEKK1 do not have gross morphological defects exceptdevelopment observed in Mkk42/2 embryos therefore
remains to be established. for an eyelid closure disability (Yujiri et al., 2000). In
contrast, MEKK3 deficiency causes embryonic lethalitySince Mkk42/2 and Mkk72/2 mice are not viable, the
function of these protein kinases has been studied in due to failure of embryonic angiogenesis and cardiovas-
cular development (Yang et al., 2000). Whether theseRag2/2 blastocyst complementation assays. Initial stud-
ies indicated that Mkk42/2 thymocytes and peripheral T defects are due to alterations in JNK signaling or
changes in another pathway is unclear. Mice deficientcells exhibited increased apoptotic responses and that
Mkk42/2 T cells were also defective in IL-2 secretion of MEKK2 or MEKK4 have not yet been reported. Studies
Review
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of Mekk12/2 cells indicate defects in JNK activation in the adaptor protein TAB2 (Takaesu et al., 2000). A similar
adaptor complex involving XIAP/TAB1 appears to linkresponse to a limited number of stimuli, including micro-
tubule destabilizing drugs, cold shock, reovirus infec- TAK1 with BMP receptors (Yamaguchi et al., 1999). The
mechanism of TAK1 activation involves autophosphory-tion, serum, and lysophosphatidic acid (Yujiri et al., 1998,
2000). In contrast, an independently created clone of lation of the T-loop (Kishimoto et al., 2000).
It is possible that TRAF adaptor proteins may be in-Mekk1-disrupted ES cells was found to be defective in
JNK activation in response to all stimuli tested (Xia et volved in the activation of the JNK pathway by many
stimuli. For example, the effects of endoplasmic reticu-al., 2000). This stronger phenotype may be a conse-
quence of the strategy used for gene targeting, which lum stress on JNK activation appears to be mediated by
the recruitment of TRAF2 to the transmembrane proteinresulted in the expression of a large fragment of MEKK1
that may act as a dominant-negative. Nevertheless, kinase IRE1 (Urano et al., 2000). However, it is likely that
other adaptor proteins contribute to the activation ofthese data do establish that MEKK1 can function as a
component of the JNK signaling pathway. Studies of the JNK pathway. Thus, a role for a group of GADD45-
related molecules in the activation of MEKK4 has beenthe functional consequence of Mekk1 gene disruption
indicate defects in cell migration and increased apopto- reported (Takekawa and Saito, 1998), although this has
been questioned by more recent studies (Sheikh et al.,sis in response to microtubule destabilizing drugs.
Whether these defects are due to changes in JNK activ- 2000). Nevertheless, studies to identify the role of other
potential adaptor molecules that mediate activation ofity or to changes in other signaling pathways that may
be regulated by MEKK1 is unclear. MAPKKK are warranted.
Molecular Scaffold Proteins Assemble JNKMechanism of MAPKKK Activation
Several lines of evidence indicate that Rho family Signaling Modules
Protein–protein interactions are thought to be criticalGTPases mediate the activation JNK by some stimuli
(Coso et al., 1995; Minden et al., 1995). The function of for the normal function of the JNK signaling pathway.
Indeed, signaling specificity may be mediated throughRho proteins is reviewed in this issue of Cell (Bar-Sagi
and Hall, 2000 [this issue of Cell]). Potential targets of the formation of protein complexes. These complexes
may involve the interaction between kinase componentsRho family GTPases include several members of the
mixed-lineage protein kinase group and MEKK group of the signaling module or interactions with another pro-
tein. Studies of budding yeast have established thatof MAPKKK (Fanger et al., 2000). Signal transduction
pathways that activate Rho proteins include tyrosine both types of complexes participate in the generation of
signaling specificity (reviewed by Whitmarsh and Davis,kinases (Schlessinger, 2000 [this issue of Cell]). Thus,
Rho proteins may mediate the activation of JNK caused 1998). First, the osmosensing MAPK Hog1p binds to the
MAPKK Pbs2p as part of a multiprotein complex thatby receptor tyrosine kinases. However, alternative
mechanisms of JNK activation may also contribute to includes the MAPKKK Ste11p. Second, the mating path-
way MAPK Fus3p binds to the scaffold protein Ste5ptyrosine kinase signaling. Thus, the adaptor protein Nck
and the Ste20-like protein kinase NIK may mediate JNK together with the MAPKK Ste7p and the MAPKKK
Ste11p. Examples of these types of complexes haveactivation by Eph receptors (Becker et al., 2000).
The activation of JNK by cytokine receptors appears been identified in mammalian cells (Whitmarsh and
Davis, 1998). Complexes similar to Pbs2p have beento be mediated by the TRAF group of adaptor proteins
(Liu et al., 1996). Activation of the TNF receptor leads defined for MKK4 and MEKK protein kinases (Xia et al.,
1998; Cheng et al., 2000). These complexes may mediateto recruitment of TRAF2, which is required for JNK acti-
vation (Yeh et al., 1997). This adaptor protein has been JNK activation by forming sequential binary complexes,
but it is possible that these proteins may also form largerreported to bind MEKK1 (Baud et al., 1999) and ASK1
(Nishitoh et al., 1998). The mechanism of TRAF2 action assemblies of signaling molecules (Figure 3). Recently,
scaffold proteins have also been identified in mamma-on MEKK1 is unclear. However, it has been demon-
strated that the effect of TRAF2 on ASK1 requires the lian cells. One example is MP1, which interacts with the
MAPK ERK1 and the MAPKK MEK1 (Schaeffer et al.,prior dissociation of ASK1 from the inhibitor thioredoxin
(Liu et al., 2000) and is likely to involve regulated ASK1 1998). Scaffold proteins for the JNK group of MAPK have
also been identified. These include the JNK interactingdimerization mediated by reactive oxygen species (Go-
toh and Cooper, 1998). Whether MEKK1 and ASK1 serve protein (JIP) group of putative scaffolds (Figure 3).
The JIP1 and JIP2 proteins are closely related proteinsnonredundant functions in the TRAF2 pathway and
whether there are roles for additional MAPKKK in this that bind to JNK, MKK7, and mixed-lineage protein ki-
nases (Whitmarsh et al., 1998; Yasuda et al., 1999).signaling pathway is unclear.
A role for TRAF proteins in the activation of JNK by Transfection assays demonstrate that these JIP proteins
potentiate JNK activation by mixed-lineage protein ki-the IL-1 receptor has also been established. The IL-1
receptor recruits TRAF6, which is required for JNK acti- nases. The JIP1 and JIP2 proteins contain an SH3 do-
main and a PTB domain within the COOH-terminal re-vation (Lomaga et al., 1999). Two possible mediators
of TRAF6 have been reported. First, TRAF6 has been gion. The PTB domain has been reported to interact with
p190 RhoGEF (Meyer et al., 1999), the reelin receptorreported to bind MEKK1 (Baud et al., 1999) although
this interaction may be mediated by the adaptor protein ApoER2 (Stockinger et al., 2000), and with the LDL re-
ceptor–related protein and Megalin (Gotthardt et al.,ECSIT (Kopp et al., 1999). The ECSIT adaptor protein
appears to increase MEKK1 activity via proteolytic pro- 2000). However, the role of the SH3 domain has not yet
been determined. The JIP1 and JIP2 proteins are mostcessing. Second, TRAF6 binds the MAPKKK TAK1 via
Cell
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Figure 3. Mammalian Scaffold Proteins Or-
ganize MAPK Signaling Pathways
MAPK signaling modules can be structur-
ally organized by interactions of MAPKKK,
MAPKK, and MAPK with scaffold proteins.
These complexes may also include Ste20-
related protein kinases (e.g., HPK1 and NIK).
The protein kinases that form the signaling
module may interact individually with a scaf-
fold protein like JIP-1. This type of scaffold
assembly is similar to that described for the
yeast scaffold protein Ste5p. A second type
of scaffold assembly that has been described
requires that one protein kinase interacts with
the other protein kinases that form the signal-
ing module. The MAPKKK MEKK1 is repre-
sentative of this class of scaffold assembly
and is similar to the Pbs2p scaffold in yeast. A third scaffold that functions within the ERK1 MAPK pathway has been described (MP1) which
also interacts with MEK1. These scaffolds are thought to organize MAPK signaling modules to function in response to appropriate physiological
stimulation.
highly expressed in the insulin-secreting b-cells of the Davis, 1998). Theoretical considerations indicate that a
bound JNK module will not function to amplify signals.pancreas and in neurons. Analysis of subcellular local-
ization demonstrates that the JIP proteins accumulate Instead, the assembly of the JNK module by a scaffold
protein may lead to the efficient activation of JNK withinin axonal and dendritic growth cones and appear to be
present at synapses (Yasuda et al., 1999; Pellet et al., a restricted region of the cell by a particular stimulus.
Dynamic regulation of the subcellular localization of the2000). The JIP1 and JIP2 proteins were also identified
independently as nuclear transcription factors (IB1 and scaffold would also be possible. An important question
relates to the mechanism by which the scaffold potenti-IB2) that exhibit sequence-specific DNA binding activity
and are proposed to regulate the expression of the insu- ates signaling through the kinase cascade. The bound
signaling molecules may interact more efficiently be-lin gene and the glucose transporter GLUT2 gene (Bonny
et al., 1998; Negri et al., 2000). The potential role of cause of increased local concentration. Furthermore,
since both MKK7 and JNK must be activated by dualthe JIP proteins as transcription factors is intriguing.
However, the DNA binding activity of JIP proteins has phosphorylation, the tethering of molecules to the scaf-
fold may increase the processivity of phosphorylationonly been detected in Southwestern blots and several
studies indicate that the JIP proteins appear to be ex- and thus increase activation. Since JIP1, JIP2, and JIP3
appear to act as dimers, it is likely that the kinase cas-cluded from the nucleus. In addition, the effects of JIP
overexpression on gene expression may be mediated cade may function within the dimer in trans rather than
in cis (Yasuda et al., 1999; Kelkar et al., 2000). Structuralby changes in JNK activity. Further studies are required
to determine whether the JIP proteins do function as analysis of the scaffold complexes will be critical for
understanding the the molecular mechanism that ac-transcription factors under certain circumstances.
Studies of the human Jip1 gene have led to the identifi- counts for the observed potentiation of JNK signaling.
Furthermore, gene knockout studies will be required tocation of missense mutations that segregate with type
II diabetes (Waeber et al., 2000). This analysis indicates establish the role of JIP proteins as scaffolds for the
JNK signaling pathway.that Jip1 is a candidate maturity onset diabetes of the
young (MODY) gene. Transfection assays and antisense It is likely that the JIP group of putative scaffold pro-
teins represents only one of several groups of proteinsoligonucleotide experiments suggest that JIP1 regu-
lates pancreatic b-cell apoptosis (Bonny et al., 2000). that may assemble a functional JNK signaling module.
For example, recent studies have established that theThese data suggest that the JNK signaling pathway may
be relevant to b-cell pathology. actin binding protein filamin may function as a putative
scaffold for the assembly of a cytokine receptor moduleThe JIP3 protein is structurally unrelated to the JIP1
and JIP2 proteins. However JIP3, like JIP1 and JIP2, that activates JNK (Marti et al., 1997; Leonardi et al.,
2000). Binding assays demonstrate that filamin interactsbinds to the MAPK JNK, the MAPKK MKK7, and mem-
bers of the mixed-lineage group of MAPKKK (Kelkar et with MKK4 and TRAF2. Additional components of the
JNK signaling module may also be assembled by filamin.al., 2000). An alternatively spliced variant of JIP3 has
been reported (JSAP) which also appears to function as Thus, studies of Drosophila indicate interactions of fil-
amin with Tube and Toll (Edwards et al., 1997). Analysisa scaffold protein for the JNK signaling pathway (Ito et
al., 1999). However, JSAP was reported to interact with of filamin-deficient melanoma cells demonstrates that
filamin appears to be required for JNK activation causedthe module JNK, MKK4, and MEKK1. Comparative stud-
ies of these proteins are warranted to confirm these by TNF. Together, these data establish that filamin is a
putative scaffold protein that may function in a cytokinedifferences in protein interactions. Nevertheless, both
of these spliced forms of JIP3 are reported to potentiate receptor signaling pathway that lead to JNK activation.
JNK signaling.
The JIP proteins have been proposed to act as molec- The JNK-Dependent Apoptotic Signaling Pathway
The JNK pathway is activated by the exposure of cellsular scaffolds that organize the JNK signal transduction
pathway in response to specific stimuli (Whitmarsh and to stress. However, the role of JNK in the stress-
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Figure 4. Role of the JNK Signaling Pathway in Stress-Induced Apoptosis
The caspase apoptotic machinery is illustrated in a simplified cartoon. Effector caspases, including caspase-3, are activated by initiator
caspases that are activated by cell surface death receptors (caspase-8) and by the mitochondrial pathway (caspase-9). JNK is not required
for death receptor signaling, but is required for caspase-9 activation by the mitochondrial pathway (Tournier et al., 2000). Potential targets of
JNK include members of the Bcl2 group of apoptotic regulatory proteins.
response is unclear. It is possible that JNK may mediate by JNK and may lead to autocrine or paracrine death
signaling (Faris et al., 1998; Kasibhatla et al., 1998). How-some of the effects of stress on cells. Alternatively, JNK
ever, it is not clear that defects in Fas-L or Fas blockactivation may represent a protective response that is
JNK-dependent apoptosis. Furthermore, targeted dis-initiated by the exposure to stress. The specific role of
ruption of the gene that encodes the adaptor proteinJNK may therefore depend upon the cellular context.
FADD, which is required for Fas-induced apoptosis,Indeed, the JNK pathway has been implicated in both
does not eliminate stress-induced apoptosis (Yeh et al.,apoptosis and survival signaling (reviewed by Ip and
1998). The expression of Fas-L may therefore contributeDavis, 1998).
to JNK-induced apoptosis, but it does not appear to beInitial studies of the role of JNK in apoptosis/survival
essential for the function of JNK.signaling were performed by investigating neuronal cell
One potential target of pro-apoptotic signaling by JNKdeath in response to neurotrophic factor withdrawal (Xia
is the tumor suppressor p53. JNK phosphorylates mu-et al., 1995). Transfection assays using dominant-nega-
rine p53 on Ser-34 in vitro (Milne et al., 1995). This phos-tive and gain-of-function components of the JNK path-
phorylation site is not conserved in human p53. How-way demonstrated that JNK contributed to the apoptotic
ever, it has been reported that human p53 is also aresponse. Furthermore, it was found that JNK-depen-
JNK substrate (Fuchs et al., 1998b). Binding to JNKdent apoptosis was suppressed by activation of survival
was reported to destabilize p53 by promoting ubiquitin-pathways (e.g., ERK MAPK and Akt/PKB). This role for
mediated degradation (Fuchs et al., 1998a). Conversely,
JNK in stress-induced neuronal cell death has been con-
when JNK is activated in cells exposed to stress, JNK
firmed in studies of mice with targeted disruption of the was reported to phosphorylate p53, inhibit ubiquitin-
neuronal gene Jnk3 (Yang et al., 1997b). The Jnk32/2 mediated degradation, and thus stabilize the p53 protein
mice are developmentally normal, but are severely (Fuchs et al., 1998b). These data suggest that JNK may
defective in the apoptotic response to excitotoxins. A be important for controlling the level of p53 expression
similar defect was observed in mice with a germ-line by regulating the half-life of p53. However, more recent
mutation in the c-Jun gene that replaced the JNK phos- studies demonstrate that JNK is not required for ultravio-
phorylation sites with Ala (Behrens et al., 1999). To- let (UV) radiation–induced accumulation of p53 (Tournier
gether, these data suggest that JNK and c-Jun may et al., 2000). Thus, JNK may contribute to the regulation
mediate a transcription-dependent apoptotic signaling of p53 stability, but JNK is not essential for this process.
pathway in neurons. Furthermore, p53 does not appear to be required for
The transcriptional targets of the apoptotic JNK sig- JNK-induced apoptosis (Chen and Tan, 2000). The po-
naling pathway have not been established. A systematic tential role of p53 as a target of JNK signaling is therefore
analysis of gene expression in wild-type and Jnk32/2 unclear. However, it is possible that JNK may regulate
mice will be required to identify the physiologically im- other aspects of p53 function. For example, since c-Jun
portant JNK-responsive genes. However, progress in can repress the p53 promoter, it is possible that JNK
this area has been made by studies of candidate genes. may regulate transcription of the p53 gene (Schreiber
et al., 1999).One example is the observation that Fas-L is induced
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Another potential target of pro-apoptotic signaling by
JNK is the transcription factor c-Myc. Recent studies
indicate that c-Myc interacts with JNK and is phosphory-
lated on Ser-62 and Thr-71 (Noguchi et al., 1999). Apo-
ptosis induced by ectopic c-Myc expression in serum-
starved cells is associated with increased JNK activity.
In addition, dominant-negative experiments suggest
that JNK signaling may participate in c-Myc stimulated
apoptosis. However, since JNK-induced apoptosis does
not require either ectopic c-Myc expression or serum
starvation, the role of c-Myc phosphorylation by JNK is
unclear.
The considerations outlined above indicate that a new
approach that allows the direct biochemical analysis of
apoptotic signaling in the absence of JNK is required.
Targeted gene knockout experiments in mice provided
an opportunity for this analysis. Disruption of the Jnk1,
Jnk2, and Jnk3 genes in mice (Table 1) causes no obvi-
ous phenotypic abnormalities. Mice with compound mu-
tations in Jnk1 plus Jnk3 or Jnk2 plus Jnk3 are also
Figure 5. A Genetic Pathway that Mediates Stress-Induced Apo-viable. In contrast, compound mutations of the two ubiq-
ptosisuitously expressed genes Jnk1 and Jnk2 causes early
Targeted gene disruptions in mice have led to the identification ofembryonic death associated with defects in neuronal
several genes that are required for stress-induced apoptosis. Thus,
apoptosis and exencephaly (Kuan et al., 1999; Sabapa- the apoptotic response to UV radiation is suppressed in the absence
thy et al., 1999b). Primary murine embryo fibroblasts of JNK (Tournier et al., 2000), cytochrome c (Li et al., 2000), Apaf-1
(MEF) prepared from Jnk12/2 Jnk22/2 embryos lack ex- (Yoshida et al., 1998), initiator caspase-9 (Hakem et al., 1998; Kuida
et al., 1998), and the effector caspase-3 (Woo et al., 1998). Thepression of both JNK protein and JNK activity (Tournier
genes encoding these proteins describe a genetic pathway requiredet al., 2000). The absence of JNK in these cells reflects
for stress-induced cell death.the neuronal-specific expression pattern of the Jnk3
gene. These Jnk null MEF represent a powerful model
system for the analysis of JNK-induced apoptosis. The release of other mitochondrial pro-apoptotic molecules,
Jnk null MEF exhibit no defects in Fas-induced apopto- including AIF and Smac/DIABLO.
sis, indicating that JNK is not required for death receptor The recognition that JNK is a component of the stress-
signaling mediated by the initiator capase-8 (Figure 4). induced apoptotic signaling mechanism provides a ge-
In contrast, the Jnk null MEF exhibited profound defects netic framework for further analysis of this signaling
in stress-induced apoptosis. Defects were observed in pathway. Targeted gene disruptions in mice have led to
the apoptotic response to UV radiation, to the transla- the identification of several genes that are required for
tional inhibitor anisomycin and to the DNA alkylating stress-induced apoptosis (Figure 5). Thus, the apoptotic
agent methylmethanesulfonate. The defect in apoptosis response to UV radiation is suppressed in the absence
was caused by the failure of activation of effector cas- of JNK (Tournier et al., 2000), cytochrome c (Li et al.,
pases, including caspase-3 (Tournier et al., 2000). These 2000), Apaf-1 (Yoshida et al., 1998), initiator caspase-9
data establish that the JNK signaling pathway is required (Hakem et al., 1998; Kuida et al., 1998), and the effector
for the response to some, but not all, apoptotic stimuli. caspase-3 (Woo et al., 1998). The genes encoding these
This conclusion has been confirmed by genetic analysis proteins describe a genetic pathway that is required for
of JNK-dependent apoptosis in Drosophila (Adachi- stress-induced cell death.
Yamada et al., 1999) and also by the observation that The observation that JNK is required for the stress-
JNK-deficiency causes defects in thymocyte apoptosis induced release of mitochondrial cytochrome c (Tour-
(Rincon et al., 1998; Sabapathy et al., 1999a). nier et al., 2000) provides an explanation for findings
reported in previous studies of the role of JNK in apo-
ptotic signaling (reviewed by Chen and Tan, 2000). Thus,Mechanism of JNK-Dependent Apoptosis
The biochemical defect in the stress-induced apoptosis JNK is not required for death receptor signaling medi-
ated by caspase-8, but is required for stress-inducedof Jnk null MEF was localized to the mitochondria (Tour-
nier et al., 2000). Decreased mitochondrial membrane apoptosis mediated by the mitochondrial/caspase-9
pathway. These two caspase signaling pathways, whichpotential is a late event in the apoptotic program that
is dependent on caspase activation. The Jnk null MEF converge on the activation of the effector caspase-3,
are differentially utilized by specific apoptotic stimuliwere found to be defective in the mitochondrial depolar-
ization response to UV radiation. Furthermore, the Jnk (Figure 4). However, although these pathways are dis-
tinct, functional interactions between these pathwaysnull MEF were also defective in an early mitochondrial
response to JNK activation, the release of cytochrome have been described. For example, the mitochondrial
pathway can provide an important amplification signalc. The failure to release cytochrome c is significant be-
cause cytochrome c acts together with Apaf-1 to acti- for death receptor signaling. The involvement of the
mitochondrial pathway in death receptor signaling isvate initiator caspase-9. Furthermore, the defect in cyto-
chrome c release probably reflects a defect in the most obvious in cells where death receptor signaling
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causes a delayed apoptotic response. It may therefore ptotic BH3-only members of the Bcl2 group (Tournier
be significant that JNK signaling has been implicated in et al., 2000).
slow killing by the Fas death receptor, but not in the
rapid killing caused by Fas ligation. These consider- Role of JNK in Signaling Cell Survival
ations indicate that JNK may contribute to death receptor Although it is established that JNK contributes to some
signaling under some circumstances. Furthermore, the apoptotic responses, it is not clear that apoptosis repre-
transcription-dependent apoptotic signaling by JNK sents the only functional consequence of JNK activa-
(leading to autocrine/paracrine secretion of death li- tion. This is most obvious when one considers that most
gands) and the transcription-independent apoptotic sig- stimuli that activate JNK do not cause apoptosis. For
naling mechanism (leading to cytochrome c release) are example, most forms of environmental stress do not
not mutually exclusive. It is possible that these two cause apoptosis under conditions that are sufficient for
mechanisms may function separately, but these mecha- JNK activation. This is partly because the JNK-depen-
nisms may also cooperate to induce death. dent apoptotic signaling pathway can be blocked by
A significant question that remains concerns the mo- activation of survival signaling pathways (Xia et al.,
lecular mechanism that accounts for the function of JNK 1995). Examples of these survival pathways include NF-
in apoptotic signal transduction. JNK activation has been kB, Akt/PKB, and ERK. Thus, the JNK pathway functions
reported to induce cytochrome c release (Hatai et al., within the overall context of the state of activation of
2000), but the mechanism is unclear. One possibility is other signaling pathways. The absence of an apoptotic
that JNK phosphorylates the transcription factor c-Jun. response to JNK activation also appears to correlate
Indeed, mutation of the JNK phosphorylation sites on with the time course of JNK activation—sustained acti-
c-Jun leads to partial protection against UV-induced vation, but not transient activation, of JNK is associated
apoptosis (Behrens et al., 1999), suggesting that c-Jun with apoptosis (Chen and Tan, 2000). Many cytokines
might mediate the effects of JNK on cytochrome c re- (e.g., TNF) cause only transient JNK activation, which
lease. However, the effect of UV to cause apoptosis does not contribute to the apoptotic response (Liu et
does not require new gene expression (Tournier et al., al., 1996). What is the role of cytokine-induced JNK
2000). Thus, it is likely that the relevant target of JNK activation? One possibility is that JNK may contribute
required for cytochrome c release is present in normal to survival signaling (Reinhard et al., 1997). Cells may
cells and that JNK does not mediate apoptosis in this interpret transient JNK activation as a survival signal
system by regulating gene expression. Potential targets because of the activation state of other signaling path-
of JNK that may regulate cytochrome c release include ways within the cell. The strongest evidence in favor of
members of the Bcl2 group of apoptotic regulatory pro- this hypothesis derives from the analysis of compound
teins. Several studies indicate that the anti-apoptotic mutant Jnk12/2 Jnk22/2 embryos that exhibit increased
proteins Bcl2 and Bcl-xL are phosphorylated by JNK in apoptosis within the developing forebrain (Kuan et al.,
vitro on sites that are phosphorylated in vivo (Maundrell 1999; Sabapathy et al., 1999b). In addition, it has been
et al., 1997; Yamamoto et al., 1999). Phosphorylation on reported that integrin-mediated survival signaling can
these sites inhibits the anti-apoptotic function of Bcl2 be mediated by the JNK pathway (Almeida et al., 2000).
and Bcl-xL. This provides an elegant mechanism that These data are consistent with the hypothesis that JNK
could account for JNK signaling because the Bcl2 pro- may mediate survival signaling under specific circum-
teins are known to regulate mitochondrial cytochrome stances. Further studies are required to determine the
c release (Gross et al., 1999). However, there are two genetic and biochemical basis for the role of JNK in
problems with this potential mechanism. First, there is
survival signaling.
disagreement concerning the function of phosphoryla-
tion. One study indicates that Bcl2 phosphorylation on
Role of JNK in Tumor Developmentthe same sites may be anti-apoptotic rather than pro-
Several lines of evidence suggest that JNK plays anapoptotic (Ito et al., 1997), while other studies indicate
important role in tumor cells. Thus, it is established thatthat the function of phosphorylation is to regulate ubiqui-
Ras-induced transformation requires c-Jun (Johnson ettin-mediated degradation rather than the anti-apoptotic
al., 1996) and that Ras induces c-Jun phosphorylationproperties of Bcl2 (Breitschopf et al., 2000). The second
on sites that are phosphorylated by JNK (Pulverer etproblem concerns the identification of JNK as a kinase
al., 1991; Smeal et al., 1991). Furthermore, Ras-inducedthat phosphorylates Bcl2 in vivo. This is because many
tumorigenicity is suppressed by mutation of the JNKstimuli that activate JNK do not cause Bcl2 phosphoryla-
phosphorylation sites on c-Jun (Behrens et al., 2000). Intion and, conversely, other stimuli cause marked Bcl2
addition, it has been reported that JNK is constitutivelyphosphorylation (e.g., microtubule disrupting drugs)
activated in several tumor cell lines and that the trans-without activating JNK. These data demonstrate that
forming actions of several oncogenes have been re-the anti-apoptotic proteins Bcl2 and Bcl-xL may not be
ported to be JNK dependent (based on dominant-nega-physiological substrates of JNK. However, it is possible
tive approaches) (reviewed by Ip and Davis, 1998). Thesethat JNK could be targeted to Bcl2 or Bcl-xL under spe-
data strongly support the hypothesis that JNK is relevantcialized circumstances in the presence of an adaptor
to cancer.molecule that mediates the interaction. The existance
Although a function for JNK is implicated in cancer,of an adaptor molecule that might have this property
the mechanism of JNK action is unclear. During tumorhas not been established.
development, it is likely that JNK-dependent stress-Further studies will be required to establish the mech-
induced apoptosis must be suppressed. This would im-anism of action of JNK in pro-apoptotic signaling to the
mitochondria. Potential targets include the pro-apo- ply that components of the JNK pathway are potential
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tumor suppressor genes. Since the Jnk1 and Jnk2 genes the process of dorsal closure demonstrate that JNK is
required for Jun phosphorylation and expression of theare largely functionally redundant, it is unlikely that either
of these genes could represent a tumor suppressor. TGF-b family protein decapentaplegic (Dpp) in the cells
that form the leading edge of the lateral epithelial cellHowever, it is possible that proteins which inhibit JNK
activity, like Evi-1 and perhaps GSTp, could act as onco- sheet. Fos is also required for Dpp expression, indicat-
ing that JNK may trigger Dpp expression by activationgenes by suppressing JNK activity (Adler et al., 1999;
Kurokawa et al., 2000). In contrast, the Mkk4 and Mkk7 of an AP-1 complex composed of Fos-Jun heterodimers.
Dpp expression is required for the elongation and spread-genes are potential tumor suppressors because these
genes are not functionally redundant. Indeed, the ing of the lateral epithelial cells to cover the amnioserosa
on the dorsal surface of the developing embryo. A similarMkk4 gene has been identified as a candidate tumor
suppressor gene (Teng et al., 1997; Su et al., 1998) and process may account for the role of JNK in thorax
closure.as a candidate metastasis suppressor gene (Yoshida et
al., 1999). It is intriguing that somatic mutations in Mkk4 An important role for JNK in the establishment of epi-
thelial planar polarity has been reported (Mlodzik, 1999).have been identified in cancer patients. However, do
the homozygous Mkk4 mutations precede tumor de- This pathway involves interactions between JNK and the
Wnt signaling pathway. Genetic analysis demonstratesvelopment? Could these mutations represent a conse-
quence of chemotherapy or tumor-associated chromo- that Dishevelled may represent an important intermedi-
ate in this interaction. Dishevelled, which causes JNKsomal instability? Further studies are required to more
fully establish the significance of these somatic Mkk4 activation, also functions in the Wnt pathway (Boutros et
al., 1998). Biochemical studies confirm that Dishevelledmutations in disease. Studies to test whether the Mkk7
gene is a candidate tumor suppressor are also war- activates JNK and further implicate the scaffold protein
axin in this process (Moriguchi et al., 1999; Zhang et al.,ranted.
Established tumor cells must adopt mechanisms to 2000). The mechanism of JNK function in the establish-
ment of planar polarity is unclear.inhibit JNK-dependent apoptosis. Tumor cells may acti-
vate survival pathways that function dominantly with Further studies of the role of JNK in embryonic mor-
phogenesis in Drosophila are warranted because it isrespect to the JNK pro-apoptotic pathway (e.g., PTEN
mutations may activate Akt/PKB signaling). Alterna- likely that new molecular insight into the function of JNK
will be gained. These studies may also provide insighttively, the targets of pro-apoptotic JNK signaling may
be altered (e.g., mutated, expressed at a different level, into the role of the JNK pathway in mammalian embry-
onic morphogenesis. Gene knockout studies demon-or post-translationally modified) to suppress JNK-
dependent apoptosis. Finally, it is possible that, in the strate that the JNK signaling pathway is required for
murine embryonic viability. JNK appears to be requiredcontext of a tumor cell (e.g., loss of p53 or Rb pathways),
JNK activation may be interpreted as an anti-apoptotic for normal apoptosis in the developing embryo, but fur-
ther studies are required to define the embryonic defectsor growth signal. Recent investigations using anti-sense
JNK oligonucleotides support the conclusion that JNK that are caused by JNK signaling deficiency in mamma-
lian embryos.functions differently in normal and tumor cells. These
studies demonstrate that JNK is required for stress-
induced apoptosis of primary cells (Garay et al., 2000; Concluding Remarks
Ho et al., 2000). In contrast, anti-sense JNK oligonucleo- The JNK signal transduction pathway is implicated in
tides inhibit the growth of tumor cells and can induce many pathological conditions, including cancer. JNK may
apoptosis (Bost et al., 1999; Potapova et al., 2000). also mediate cardiac hypertrophic responses (Wang et
These studies imply that JNK inhibition may be useful al., 1998), ischemia/reperfusion injury to the heart and
for tumor therapy. Furthermore, these studies indicate kidney (He et al., 1999; Garay et al., 2000), endothelial
that genetic interactions with cancer-associated genes cell apoptosis caused by diabetes-associated hypergly-
may be critical for determining the outcome of JNK sig- cemia (Ho et al., 2000), and pancreatic b-cell apoptosis
naling. associated with diabetes (Bonny et al., 2000). JNK has
also been implicated in several neurodegenerative dis-
eases (Yang et al., 1997b). The JNK signaling pathwayRole of the JNK Signaling Pathway
in Embryonic Morphogenesis therefore represents a potential target for therapeutic
intervention. A goal for future studies will be to establishThe JNK protein kinases are not present in yeast, but
JNK but has been identified in nematodes (Kawasaki et whether JNK directly contributes to these disease pro-
cesses and to define the molecular mechanism of JNKal., 1999) and insects (Riesgo-Escovar et al., 1996; Sluss
et al., 1996). In the nematode Caenorhabditis elegans, function.
A key fundamental question that remains unresolvedJNK is required for the normal function of GABAergic
motor neurons, but does not appear to be essential for concerns the ability of cells to interpret JNK activation
in different ways depending upon context (e.g., survivalembryonic morphogenesis. In contrast, genetic studies
of Drosophila melanogaster demonstrate that JNK is signaling versus apoptosis). It is likely that this ability
is mediated by interactions of JNK with other signal-required for embryonic epithelial cell sheet movements
and epithelial planar polarity. ing pathways within the cell. The combinatorial actions
of transcription factors on gene promoters suggestsJNK is required for at least two morphogenetic pro-
cesses that involve epithelial cell sheet movements: dor- one possible mechanism by which JNK-activated AP-1
could lead to different outcomes in different contexts.sal closure and thorax closure (reviewed by Ip and Davis,
1998; Leppa and Bohmann, 1999). Detailed studies of In conclusion, progress has been made toward under-
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its proteasome-dependent degradation: molecular characterizationstanding the function of the JNK pathway. Many of the
of the involved signaling pathway. Mol. Cell. Biol. 20, 1886–1896.components of this signaling pathway have now been
Chen, Y.R., and Tan, T.H. (2000). The c-Jun N-terminal kinase path-identified. Research during the next few years will be
way and apoptotic signaling. Int. J. Oncol. 16, 651–662.exciting because we will begin to uncover basic molecu-
Chen, C.Y., Gherzi, R., Andersen, J.S., Gaietta, G., Jurchott, K.,lar mechanisms and gain biological insight into the func-
Royer, H.D., Mann, M., and Karin, M. (2000). Nucleolin and YB-1 aretion of JNK.
required for JNK-mediated interleukin-2 mRNA stabilization during
T-cell activation. Genes Dev. 14, 1236–1248.
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